<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072163</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02560</org_study_id>
    <secondary_id>CALGB-500102</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CDR0000335518</secondary_id>
    <nct_id>NCT00072163</nct_id>
  </id_info>
  <brief_title>Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma</brief_title>
  <official_title>A Phase II Study Of Temozolomide And Thalidomide In Patients With Metastatic Melanoma In The Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving temozolomide together with thalidomide works&#xD;
      in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy,&#xD;
      such as temozolomide, work in different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the&#xD;
      tumor. Combining temozolomide with thalidomide may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Primary I. Determine the objective response rate in patients with brain&#xD;
      metastases secondary to melanoma treated with temozolomide and thalidomide.&#xD;
&#xD;
      Secondary I. Determine the toxic effects of and tolerance to this regimen in these patients.&#xD;
&#xD;
      II. Determine the objective response rate in extracranial metastases of patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      III. Determine the time to first disease progression (intra- or extracranial) in patients&#xD;
      treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on&#xD;
      days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients achieving complete response (CR) receive 2 additional courses of therapy&#xD;
      beyond CR.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 1.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (defined as complete or partial)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>90% confidence intervals will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first progression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <condition>Tumors Metastatic to Brain</condition>
  <arm_group>
    <arm_group_label>Treatment (temozolomide, thalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (temozolomide, thalidomide)</arm_group_label>
    <other_name>SCH 52365</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (temozolomide, thalidomide)</arm_group_label>
    <other_name>Kevadon</other_name>
    <other_name>Synovir</other_name>
    <other_name>THAL</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic melanoma&#xD;
&#xD;
          -  Clinical evidence of brain metastases&#xD;
&#xD;
               -  At least 1 unidimensionally measurable brain lesion at least 2.0 cm by&#xD;
                  conventional techniques OR at least 1.0 cm by spiral CT scan or MRI&#xD;
&#xD;
                    -  The following lesions are not considered measurable:&#xD;
&#xD;
                         -  Bone lesions&#xD;
&#xD;
                         -  Leptomeningeal disease&#xD;
&#xD;
                         -  Ascites&#xD;
&#xD;
                         -  Pleural/pericardial effusion&#xD;
&#xD;
                         -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                         -  Abdominal masses that are not confirmed and followed by imaging&#xD;
                            techniques&#xD;
&#xD;
                         -  Cystic lesions&#xD;
&#xD;
                         -  Lesions situated in a previously irradiated area, unless new growth is&#xD;
                            documented&#xD;
&#xD;
          -  Performance status - CTC 0-1&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Lactic dehydrogenase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  No history of active angina&#xD;
&#xD;
          -  No history of significant ventricular arrhythmia&#xD;
&#xD;
          -  No history of deep vein thrombosis&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No acute abnormality by EKG&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
          -  No history of pulmonary embolism&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 1 highly-effective and 1 additional method of contraception&#xD;
             for 28 days before, during, and for 4 weeks after study participation&#xD;
&#xD;
          -  No known HIV disease&#xD;
&#xD;
          -  Thyroid-stimulating hormone normal&#xD;
&#xD;
          -  Serum anticonvulsant levels normal (for patients on anticonvulsants)&#xD;
&#xD;
          -  No frequent vomiting and/or any other medical condition (e.g., partial bowel&#xD;
             obstruction) that would preclude oral medication intake&#xD;
&#xD;
          -  No preexisting neuropathy greater than grade 1&#xD;
&#xD;
          -  No uncontrolled seizures&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude study participation&#xD;
&#xD;
          -  At least 4 weeks since prior cytokines&#xD;
&#xD;
               -  Biologic agents used as adjuvants, vaccines, and cellular therapies do not&#xD;
                  require a 4-week washout period&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
          -  No prior chemotherapy for brain metastases&#xD;
&#xD;
          -  No prior continuous daily temozolomide&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except steroids and hormones administered for&#xD;
             non-disease-related conditions (e.g., insulin for diabetes) or for control of&#xD;
             intracranial edema from brain metastases&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior whole brain radiotherapy (WBRT) allowed provided patient has progressive disease&#xD;
             in a measurable CNS lesion&#xD;
&#xD;
          -  Prior stereotactic radiotherapy allowed provided patient has progressive disease in a&#xD;
             measurable CNS lesion&#xD;
&#xD;
          -  At least 4 weeks since prior WBRT&#xD;
&#xD;
          -  At least 3 weeks since prior stereotactic radiosurgery&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior surgical resection&#xD;
&#xD;
          -  No concurrent warfarin or heparin products or their derivatives&#xD;
&#xD;
          -  No concurrent antiplatelet therapy (e.g., daily aspirin, ibuprofen, or clopidogrel&#xD;
             bisulfate)&#xD;
&#xD;
          -  No concurrent bisphosphonates (e.g., zoledronate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Krown</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

